Profit from Neurocrine Biosciences Inc (Nasdaq). Within 2 hours. Traded 400 units. Capital deployed $7,500
Neurocrine develops pharmaceutical through its R&D platform, focused on neurological and endocrine based diseases and disorders. We are not sure what it really means or how to value this company, but we know the stock price move a bit.